Item | Value | Source |
LDL cholesterol reductions with statin therapy: | ||
| 37%–43%; 43% used | Meta-analysis of randomised controlled trials12 |
| 48%–58%; 55% used | Meta-analysis of randomised controlled trials12 |
Effects of statin therapy on cardiovascular events per 1 mmol/L reduction in LDL cholesterol, Risk Ratio (RR) (95% CI) | Cholesterol Treatment Trialists’ Collaboration individual participant data meta-analysis2 | |
| RR 0.76 (0.73 to 0.79) | |
| RR 0.84 (0.80 to 0.89) | |
| RR 0.75 (0.73 to 0.78) | |
| RR 0.88 (0.85 to 0.91) | |
Adverse effects of statin therapy on: | ||
Incident diabetes, OR (95% CI) | ||
| OR 1.09 (1.02 to 1.17) | Meta-analyses of randomised controlled trials13 |
| OR 1.12 (1.04 to 1.22) | Meta-analyses of randomised controlled trials14 |
Myopathy | ||
| 11 (4 to 27) | Overview of cohort studies15 |
| 0.017 QALY reduction in year of event | Modelling study.16 |
Rhabdomyolysis | ||
| 3.4 (1.6 to 6.5) | Overview of cohort studies15 |
| 10% | Overview of cohort studies15 |
| 50% over 7.5 days hospital admission and by 20% for further 30 days recovery | Modelling study.16 |
Statin therapy costs | ||
| £14.09 to £19.57 per year; £14.35 used in base-case | NHS Drug tariff, December 202117 |
| £15.91 to £27.91 per year; £21.91 used in base-case | NHS Drug tariff, December 202117 |
Statin initiation and monitoring healthcare costs | ||
| £54.65 | Unit costs for Health and Social Care18; NHS reference costs19 |
| £12.05 | Unit costs for Health and Social Care18; NHS reference costs19 |
CVD, cardiovascular disease; HbA1c, hemoglobin A1C ; LDL, low-density lipoprotein; NHS, National Health Service England; NICE, National Institute for Health and Care Excellence; OR, odds ratio; QoL, quality of life; RR, relative risk.